198 related articles for article (PubMed ID: 38372852)
1. Who Should Receive Immunotherapy for Advanced Gastroesophageal Cancer?
Khateeb S; Cavalcante L; Alnairat N; Singh M; Sahin IH; Saeed A; Saeed A
Curr Treat Options Oncol; 2024 Apr; 25(4):496-509. PubMed ID: 38372852
[TBL] [Abstract][Full Text] [Related]
2. Nivolumab with or without chemotherapy for metastatic gastroesophageal cancers and future perspectives.
Sewastjanow-Silva M; Yamashita K; Rosa Vicentini E; Hirschmann M; Pool Pizzi M; Trail AM; Waters RE; Rogers JE; Ajani JA
Expert Rev Anticancer Ther; 2022 Nov; 22(11):1177-1181. PubMed ID: 36266061
[TBL] [Abstract][Full Text] [Related]
3. Recent progress and current challenges of immunotherapy in advanced/metastatic esophagogastric adenocarcinoma.
Moehler M; Högner A; Wagner AD; Obermannova R; Alsina M; Thuss-Patience P; van Laarhoven H; Smyth E
Eur J Cancer; 2022 Nov; 176():13-29. PubMed ID: 36183651
[TBL] [Abstract][Full Text] [Related]
4. Immunotherapy and Targeted Therapy for Advanced Gastroesophageal Cancer: ASCO Guideline.
Shah MA; Kennedy EB; Alarcon-Rozas AE; Alcindor T; Bartley AN; Malowany AB; Bhadkamkar NA; Deighton DC; Janjigian Y; Karippot A; Khan U; King DA; Klute K; Lacy J; Lee JJ; Mehta R; Mukherjee S; Nagarajan A; Park H; Saeed A; Semrad TJ; Shitara K; Smyth E; Uboha NV; Vincelli M; Wainberg Z; Rajdev L
J Clin Oncol; 2023 Mar; 41(7):1470-1491. PubMed ID: 36603169
[TBL] [Abstract][Full Text] [Related]
5. Immunotherapy in Gastric Cancer.
Högner A; Moehler M
Curr Oncol; 2022 Mar; 29(3):1559-1574. PubMed ID: 35323331
[TBL] [Abstract][Full Text] [Related]
6. Immunotherapy for Esophageal and Gastric Cancer.
Kelly RJ
Am Soc Clin Oncol Educ Book; 2017; 37():292-300. PubMed ID: 28561677
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of PD-1/PD-L1 inhibitors in advanced gastroesophageal cancer based on characteristics: a meta-analysis.
Liu W; Huo G; Chen P
Immunotherapy; 2023 Jul; 15(10):751-771. PubMed ID: 37190983
[TBL] [Abstract][Full Text] [Related]
8. Immunotherapy in Gastroesophageal Cancers: Current Evidence and Ongoing Trials.
Huynh J; Patel K; Gong J; Cho M; Malla M; Parikh A; Klempner S
Curr Treat Options Oncol; 2021 Sep; 22(11):100. PubMed ID: 34524553
[TBL] [Abstract][Full Text] [Related]
9. Beyond the PD-L1 horizon: In search for a good biomarker to predict success of immunotherapy in gastric and esophageal adenocarcinoma.
Koemans WJ; Chalabi M; van Sandick JW; van Dieren JM; Kodach LL
Cancer Lett; 2019 Feb; 442():279-286. PubMed ID: 30419350
[TBL] [Abstract][Full Text] [Related]
10. Immunotherapy Advances in Urothelial Carcinoma.
Jain RK; Snyders T; Nandagopal L; Garje R; Zakharia Y; Gupta S
Curr Treat Options Oncol; 2018 Dec; 19(12):79. PubMed ID: 30554335
[TBL] [Abstract][Full Text] [Related]
11. Immune Checkpoint Inhibitors in Pre-Treated Gastric Cancer Patients: Results from a Literature-Based Meta-Analysis.
Roviello G; Corona SP; D'Angelo A; Rosellini P; Nobili S; Mini E
Int J Mol Sci; 2020 Jan; 21(2):. PubMed ID: 31936762
[TBL] [Abstract][Full Text] [Related]
12. Comparative efficacy and safety of immunotherapies targeting the PD-1/PD-L1 pathway for previously treated advanced non-small cell lung cancer: A Bayesian network meta-analysis.
Almutairi AR; Alkhatib N; Martin J; Babiker HM; Garland LL; McBride A; Abraham I
Crit Rev Oncol Hematol; 2019 Oct; 142():16-25. PubMed ID: 31326706
[TBL] [Abstract][Full Text] [Related]
13. Immune Checkpoint Inhibitors in the Treatment of Gastroesophageal Cancer.
Chénard-Poirier M; Smyth EC
Drugs; 2019 Jan; 79(1):1-10. PubMed ID: 30604292
[TBL] [Abstract][Full Text] [Related]
14. Targeting the PD-1 pathway: a new hope for gastrointestinal cancers.
Bilgin B; Sendur MA; Bülent Akıncı M; Şener Dede D; Yalçın B
Curr Med Res Opin; 2017 Apr; 33(4):749-759. PubMed ID: 28055269
[TBL] [Abstract][Full Text] [Related]
15. Current state of the art: immunotherapy in esophageal cancer and gastroesophageal junction cancer.
Li N; Sohal D
Cancer Immunol Immunother; 2023 Dec; 72(12):3939-3952. PubMed ID: 37995002
[TBL] [Abstract][Full Text] [Related]
16. FDA Approval Summary: Pembrolizumab for Recurrent Locally Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Expressing PD-L1.
Fashoyin-Aje L; Donoghue M; Chen H; He K; Veeraraghavan J; Goldberg KB; Keegan P; McKee AE; Pazdur R
Oncologist; 2019 Jan; 24(1):103-109. PubMed ID: 30120163
[TBL] [Abstract][Full Text] [Related]
17. PD-1 inhibitors in esophageal cancer: a systematic review of the oncological outcomes associated with PD-1 blockade and the evolving therapeutic paradigm.
Whooley J; Alazzawi M; Donlon NE; Bolger JC; Robb WB
Dis Esophagus; 2022 May; 35(5):. PubMed ID: 34553222
[TBL] [Abstract][Full Text] [Related]
18. Nivolumab combination therapy as first-line treatments for unresectable, advanced or metastatic esophageal squamous cell carcinoma.
Rogers JE; Yamashita K; Sewastjanow-Silva M; Rosa Vicentini E; Waters R; Ajani JA
Expert Rev Anticancer Ther; 2023 Jun; 23(6):565-571. PubMed ID: 37122102
[TBL] [Abstract][Full Text] [Related]
19. Safety and efficacy of pembrolizumab in combination with S-1 plus oxaliplatin as a first-line treatment in patients with advanced gastric/gastroesophageal junction cancer: Cohort 1 data from the KEYNOTE-659 phase IIb study.
Kawazoe A; Yamaguchi K; Yasui H; Negoro Y; Azuma M; Amagai K; Hara H; Baba H; Tsuda M; Hosaka H; Kawakami H; Oshima T; Omuro Y; Machida N; Esaki T; Yoshida K; Nishina T; Komatsu Y; Han SR; Shiratori S; Shitara K
Eur J Cancer; 2020 Apr; 129():97-106. PubMed ID: 32145474
[TBL] [Abstract][Full Text] [Related]
20. Analyses of PD-L1 and Inflammatory Gene Expression Association with Efficacy of Nivolumab ± Ipilimumab in Gastric Cancer/Gastroesophageal Junction Cancer.
Lei M; Siemers NO; Pandya D; Chang H; Sanchez T; Harbison C; Szabo PM; Janjigian Y; Ott PA; Sharma P; Bendell J; Evans TRJ; de Braud F; Chau I; Boyd Z
Clin Cancer Res; 2021 Jul; 27(14):3926-3935. PubMed ID: 33782030
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]